TCA cycle enzyme inhibitors, such as the mutant isocitrate dehydrogenase (IDH) inhibitors AG-221 and AG-881, are already in clinical trials for the treatment of IDH2 or IDH1/2-mutated acute myeloid leukemia [151, 152]. This evidence concerns the gene IDH1 and acute myeloid leukemia.